Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands. Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis. MedTech segment provides electrophysiology products to treat cardiovascular diseases.
Market Cap | 431.734 Billion | Shares Outstanding | 2.631 Billion | Avg 30-day Volume | 7.217 Million |
P/E Ratio | 26.0776 | Dividend Yield | 2.4008 | EPS | 1.35 |
Price to Revenue | 5.0105 | Debt to Equity | 0.4269 | EBITDA | 27.573 Billion |
Price to Book Value | 6.2724 | Operating Margin | 23.4684 | Enterprise Value | 478.97 Billion |
Current Ratio | 1.425 | EPS Growth | 0.033 | Quick Ratio | 1.087 |
1 Yr BETA | 0.2798 | 52-week High/Low | 184.26 / 152.84 | Profit Margin | 19.2137 |
Operating Cash Flow Growth | -9.6959 | Altman Z-Score | 4.8743 | Free Cash Flow to Firm | 21.58 Billion |
Earnings Report | 2022-10-18 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
WENGEL KATHRYN E EVP, CHIEF GSC OFFICER |
|
88,052 | 2022-06-10 | 3 |
|
5,652 | 2022-06-07 | 4 | |
|
27,433 | 2022-06-07 | 4 | |
|
5,774 | 2022-06-07 | 4 | |
DECKER ROBERT J CONTROLLER, CAO |
|
16,169 | 2022-05-26 | 5 |
HAIT WILLIAM SEE REMARKS |
|
109,934 | 2022-04-21 | 5 |
MONGON THIBAUT EXEC VP, WW CHAIR, CONSUMER |
|
70,824 | 2022-03-17 | 4 |
|
25,673 | 2022-02-15 | 1 | |
|
17,706 | 2022-02-15 | 1 | |
|
24,824 | 2022-02-15 | 1 | |
|
12,197 | 2022-02-15 | 1 | |
|
3,614 | 2022-02-15 | 1 | |
|
17,706 | 2022-02-15 | 1 | |
|
10,355 | 2022-02-15 | 1 | |
|
14,323 | 2022-02-15 | 1 | |
|
1,030 | 2022-02-15 | 2 | |
|
5,133 | 2022-02-15 | 1 | |
|
2,327 | 2022-02-15 | 1 | |
MAMMEN MATHAI EVP, PHARM, R&D |
|
85,329 | 2022-02-14 | 3 |
|
822,226 | 2022-02-14 | 3 | |
FASOLO PETER EXEC VP, CHIEF HR OFFICER |
|
279,682 | 2022-02-14 | 2 |
ULLMANN MICHAEL H EXEC VP, GENERAL COUNSEL |
|
153,578 | 2022-02-14 | 2 |
DUATO JOAQUIN CEO |
|
354,457 | 2022-02-14 | 3 |
WOLK JOSEPH J EXEC VP, CFO |
|
27,322 | 2022-02-14 | 2 |
MCEVOY ASHLEY EVP, WW CHAIR, MEDICAL DEVICES |
|
115,683 | 2022-02-14 | 2 |
TAUBERT JENNIFER L EVP, WW CHAIR, PHARMACEUTICALS |
|
212,285 | 2022-02-14 | 2 |
BROADHURST VANESSA EVP, GLOBAL CORP AFF. |
|
35,818 | 2022-02-14 | 3 |
SWANSON JAMES D. EVP, CHIEF INFORMATION OFFICER |
|
1,084 | 2022-01-03 | 1 |
STOFFELS PAULUS VICE CHAIR, EXEC COMMITTEE |
|
275,547 | 2021-02-12 | 0 |
SNEED MICHAEL E EVP, GLOBAL CORP AFF & CCO |
|
66,060 | 2021-02-12 | 0 |
|
16,030 | 2020-03-13 | 0 | |
MESQUITA JORGE S. EXEC VP, WW CHAIR, CONSUMER |
|
27,344 | 2019-02-08 | 0 |
KAPUSTA RONALD A CONTROLLER, CAO |
|
18,522 | 2019-02-08 | 0 |
PETERSON SANDRA E EXEC VP, GROUP WW CHAIRMAN |
|
83,349 | 2018-02-12 | 0 |
CARUSO DOMINIC J EXEC VP, FINANCE; CFO |
|
171,986 | 2018-02-12 | 0 |
PRUDEN GARY J EXEC VP, WW CHAIR, MED DEVICES |
|
43,726 | 2017-02-28 | 0 |
|
0 | 2016-09-06 | 0 | |
|
11,952 | 2016-02-08 | 0 | |
|
0 | 2015-02-09 | 0 | |
COSGROVE STEPHEN J CORPORATE CONTROLLER |
|
0 | 2015-02-09 | 0 |
|
0 | 2015-02-09 | 0 | |
|
15,290 | 2014-02-10 | 0 | |
|
15,393 | 2013-02-11 | 0 | |
|
No longer subject to file | 2013-02-08 | 0 | |
DEYO RUSSELL C VP, GENERAL COUNSEL |
|
No longer subject to file | 2012-02-22 | 0 |
MCCOY SHERILYN S MEMBER, EXECUTIVE COMMITTEE |
|
81,370 | 2012-02-09 | 0 |
GOGGINS COLLEEN A MEMBER, EXECUTIVE COMMITTEE |
|
109,043 | 2011-01-10 | 0 |
|
10,190 | 2010-03-09 | 0 | |
FOSTER-CHEEK KAYE I VP, HUMAN RESOURCES |
|
5,797 | 2009-12-31 | 0 |
VALERIANI NICHOLAS J VP, STRATEGY & GROWTH |
|
67,429 | 2009-09-30 | 0 |
CASEY DONALD M JR. MEMBER, EXECUTIVE COMMITTEE |
|
44,960 | 2009-09-10 | 0 |
POON CHRISTINE A VICE CHAIRMAN |
|
55,889 | 2009-02-12 | 0 |
|
No longer subject to file | 2008-05-28 | 0 | |
|
7,713 | 2007-12-11 | 0 | |
|
28,777 | 2007-03-13 | 0 | |
DARRETTA ROBERT J VICE CHAIRMAN |
|
231,237 | 2007-02-16 | 0 |
PETERSON PER A EXECUTIVE COMMITTEE MEMBER |
|
32,833 | 2007-02-16 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
JOHNSON & JOHNSON JNJ | 2022-09-08 15:15:04 UTC | 2.07 | 0.25 | 0 |
JOHNSON & JOHNSON JNJ | 2022-09-08 14:45:03 UTC | 2.07 | 0.25 | 0 |
JOHNSON & JOHNSON JNJ | 2022-09-08 14:15:03 UTC | 2.07 | 0.25 | 0 |
JOHNSON & JOHNSON JNJ | 2022-09-08 13:45:03 UTC | 2.07 | 0.25 | 0 |
JOHNSON & JOHNSON JNJ | 2022-09-08 13:15:03 UTC | 2.07 | 0.25 | 0 |
JOHNSON & JOHNSON JNJ | 2022-09-08 12:45:03 UTC | 2.07 | 0.25 | 0 |
JOHNSON & JOHNSON JNJ | 2022-09-07 22:15:05 UTC | 2.07 | 0.25 | 0 |
JOHNSON & JOHNSON JNJ | 2022-09-07 21:45:05 UTC | 2.07 | 0.25 | 0 |
JOHNSON & JOHNSON JNJ | 2022-09-07 21:15:04 UTC | 2.07 | 0.25 | 0 |
JOHNSON & JOHNSON JNJ | 2022-09-07 20:45:03 UTC | 2.07 | 0.25 | 0 |
JOHNSON & JOHNSON JNJ | 2022-09-07 20:15:05 UTC | 2.07 | 0.25 | 0 |
JOHNSON & JOHNSON JNJ | 2022-09-07 19:45:04 UTC | 2.07 | 0.25 | 0 |
JOHNSON & JOHNSON JNJ | 2022-09-07 19:15:04 UTC | 2.07 | 0.25 | 0 |
JOHNSON & JOHNSON JNJ | 2022-09-07 18:45:04 UTC | 2.0364 | 0.2836 | 0 |
JOHNSON & JOHNSON JNJ | 2022-09-07 18:15:05 UTC | 2.0364 | 0.2836 | 0 |
JOHNSON & JOHNSON JNJ | 2022-09-07 17:45:04 UTC | 2.0364 | 0.2836 | 0 |
JOHNSON & JOHNSON JNJ | 2022-09-07 17:15:05 UTC | 2.0364 | 0.2836 | 0 |
JOHNSON & JOHNSON JNJ | 2022-09-07 16:45:04 UTC | 2.0059 | 0.3141 | 0 |
JOHNSON & JOHNSON JNJ | 2022-09-07 16:15:04 UTC | 2.0059 | 0.3141 | 0 |
JOHNSON & JOHNSON JNJ | 2022-09-07 15:45:04 UTC | 2.0059 | 0.3141 | 0 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Ultimus Managers Trust- WAYCROSS LONG/SHORT EQUITY FUND | JNJ | -5300.0 shares, $-813073.0 | 2020-08-31 | N-PORT |
JPMorgan Trust I- JPMorgan Research Market Neutral Fund | JNJ | -3165.0 shares, $-571155.9 | 2022-04-30 | N-PORT |
Waycross Independent Trust- WAYCROSS LONG/SHORT EQUITY FUND | JNJ | -6300.0 shares, $-1131039.0 | 2022-05-31 | N-PORT |
Weiss Strategic Interval Fund- Weiss Strategic Interval Fund | JNJ | -12058.0 shares, $-2140415.58 | 2022-06-30 | N-PORT |